MyoGene Bio
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
7098 Miratech Dr Ste 120, San Diego, Cal...Website
www.myogenebio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About MyoGene Bio
MyoGene Bio was founded in 2018 by University of California, Los Angeles researchers Drs Courtney Young, Melissa Spencer, and April Pyle, with the mission to develop cutting edge genetic therapies for muscle diseases. MyoGene Bio's lead program is a gene editing therapy, MyoDys45-55, for Duchenne muscular dystrophy, a devastating muscle wasting disease. MyoGene Bio utilizes new technologies to have a strong positive effect on disease progression by targeting the underlying cause of disease. The company philosophy is to make meaningful impacts on muscle diseases through dedication to honesty, integrity, and innovation.Explore more
MyoGene Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MyoGene Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when MyoGene Bio launches new products
Congratulate Masked Content for being promoted to Masked Content at MyoGene Bio
Check out if MyoGene Bio is spiking on competitors!
Earning: See what the market has to say on MyoGene Bio recently announced quarterly report
Funding: Get notified immidiatlly once MyoGene Bio has new funding data
MyoGene Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if MyoGene Bio had a recent Job posting/layoffs
Check if MyoGene Bio has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at MyoGene Bio
Find 3 more new buyers
Compare Similar Companies to MyoGene Bio
Compare insights from companies similar to MyoGene Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
MyoGene Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MyoGene Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MyoGene Bio.
MyoGene Bio Tech Stack
A closer look at the technologies used by MyoGene Bio
MyoGene Bio News & Media
MyoGene Granted Orphan Drug Designation and Rare Pediatric Disease Designation for Duchenne Muscular Dystrophy Program
These designations make MyoDys45-55, a gene editing therapy designed to treat up to 50% of all Duchenne patients, eligible for incentives SAN DIEGO, CA, UNITED STATES, November 19, 2024 /EINPresswire.com/ -- MyoGene Bio, a biotech dedicated to …MyoGene Bio Receives Investment From CureDuchenne Ventures
MyoGene Bio, a San Diego, CA-based biotech company developing a novel gene editing therapy for Duchenne muscular dystrophy (DMD), received an investment from CureDuchenne Ventures. The amount of the deal was not disclosed. The company intends to use the funds to advance development of MyoDys45-55, an AAV-delivered CRISPR/Cas9 gene editing approach that would be applicable […] The post MyoGene Bio Receives Investment From CureDuchenne Ventures appeared first on FinSMEs.CureDuchenne Ventures Invests in MyoGene Bio and its AAV-Delivered CRISPR/Cas9 Gene Editing Approach
NEWPORT BEACH, Calif., May 11, 2023 /PRNewswire/ -- CureDuchenne Ventures announced funding for MyoGene Bio, LLC, a biotech company developing a novel gene editing therapy for Duchenne muscular dystrophy (DMD). MyoGene will use this funding to advance development of MyoDys45-55, an...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MyoGene Bio
Sign Up For FreeTo access detailed company insights
MyoGene Bio was founded in 2018 by University of California, Los Angeles researchers Drs Courtney Young, Melissa Spencer, and April Pyle, with the mission to develop cutting edge genetic therapies for muscle diseases. MyoGene Bio's lead program is a gene editing therapy, MyoDys45-55, for Duchenne muscular dystrophy, a devastating muscle wasting dis... Read More
